FierceBiotech

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...
Monthly Prescribing Reference

Xarelto Approved to Treat and Prevent Blood Clots in Pediatric Patients

A new oral suspension formulation of Xarelto has also been approved by the FDA. The Food and Drug Administration (FDA) has approved Xarelto ® (rivaroxaban) for 2 new pediatric indications: treatment ...
Business Insider

XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

RARITAN, N.J., July 8, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged ...
The Trentonian

Janssen Submits New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

RARITAN, N.J., June 23, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...
Pharm Exec

Johnson & Johnson Reports Promising Findings for Xarelto for Reducing the Risk of Clinically Significant Bleeding

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban). Johnson & Johnson has ...
FiercePharma

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement

Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...